Výsledky vyhledávání - "Fredrik O. L. Nilsson"

Akademický článek

Prevalence of diabetes and hospitalization due to poor glycemic control in people with bladder cancer or renal cell carcinoma in Sweden

Autor: Emelie Andersson, Gunnar Brådvik, Fredrik O. L. Nilsson, Johannes Arpegård, Angela Strambi, Petter Kollberg, Katarina Steen Carlsson

Publikováno v: BMC Urology, Vol 24, Iss 1, Pp 1-12 (2024)

Abstract Background Bladder cancer (BC) and Renal cell carcinoma (RCC) are the most common urogenital cancers among both sexes, with a yearly global incidence of around 500 000 each. Both BC and RCC have been linked to diabetes. Poor glycemic control

Externí odkaz: https://doaj.org/article/272a79bae80949db8fea2fdd869bed7a

Zobrazit plný text záznamu

Cost‑Effectiveness of Lorlatinib in First-Line Treatment of Adult Patients with Anaplastic Lymphoma Kinase (ALK)‑Positive Non‑Small‑Cell Lung Cancer in Sweden

Autor: Jaesh Naik, Norma Beavers, Fredrik O. L. Nilsson, Laura Iadeluca, Chrissy Lowry

Publikováno v: Applied Health Economics and Health Policy. 21:661-672

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::16d3d355a516ce585ac6f73c11d84e90
https://doi.org/10.1007/s40258-023-00807-7

Zobrazit plný text záznamu

Use of ALK-tyrosine kinase inhibitors (ALK TKI) in clinical practice, overall survival, and treatment duration - a Swedish nationwide retrospective study

Autor: Rosa Lauppe, Fredrik O. L. Nilsson, Hanna Fues Wahl, Mathias Lilja, Anders Vikström, Sandra T. Asanin

Publikováno v: Acta oncologica (Stockholm, Sweden). 61(11)

Background The real-world treatment and outcomes of patients with anaplastic lymphoma kinase positive (ALK+) advanced non-small cell lung cancer treated with ALK Tyrosine Kinase Inhibitor (TKI) drugs in Sweden is not well described. Material and meth

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::001765b87310c582d146e94ab2d78920
https://pubmed.ncbi.nlm.nih.gov/36368902

Zobrazit plný text záznamu

Plný text ve formátu HTML

The cost-effectiveness of dacomitinib in first-line treatment of advanced/metastatic epidermal growth factor receptor mutation-positive non-small-cell lung cancer (

Autor: Fredrik O L, Nilsson, Peter, Gal, Ivan, Houisse, Jasmina I, Ivanova, Sandra T, Asanin

Publikováno v: Journal of medical economics. 24(1)

Although the benefit of first-line epidermal growth factor receptor (EGFR) tyrosine kinase inhibitors (TKIs) over chemotherapy inA partitioned survival model was developed with three health states: progression-free, post-progression, and death. Progr

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::0939aaa84aafb93648dcf985f875ed04
https://pubmed.ncbi.nlm.nih.gov/33754924

Zobrazit plný text záznamu

Cost-effectiveness analysis of newer anticholinergic drugs for urinary incontinence vs oxybutynin and no treatment using data on persistence from the Swedish prescribed drug registry

Autor: Fredrik O L, Nilsson, Love, Linnér, Eva, Samuelsson, Ian, Milsom

Publikováno v: BJU international. 110(2)

Study Type - Therapy (cost effectiveness). Level of Evidence 2a. What's known on the subject? and What does the study add? Anticholinergic drugs are a common treatment alternative in urinary incontinence, which results in large costs for caregivers.

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::fc93127f09ed3ef3a9d2002894e0bae3
https://pubmed.ncbi.nlm.nih.gov/22093912

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání